BSECompany Update16h ago · 18 Nov 2026, 03:37 pm
Please find attached.
India Glycols Ltd · 500201
✦ AI Summary▲ PositiveResults
India Glycols Ltd has released an investor presentation for Q2 & H1 FY27, highlighting strong growth momentum, healthy earnings growth, and a shift towards a specialty-led portfolio. The company's bio-based specialty materials and sustainable & performance chemicals segments are demonstrating operating leverage and expanding margins. The demerger of Spirits & Bio-fuels and Ennature Biopharma businesses has created a focused chemicals company.
Analysis Scores
Earnings Impact8/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
India Glycols Ltd - 500201 - Announcement under Regulation 30 (LODR)-Investor Presentation
Attachments (1)
📄pdf
Download →
b2e33d12-c614-46a5-9725-e5c4f1b34d22.pdf
View document text
IGL/SE/2026-27/79
18th November, 2026
The Manager (Listing) The Manager (Listing)
BSE Limited National Stock Exchange of India Limited
1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G,
Rotunda Building, P.J. Towers, Bandra Kurla Complex,
Dalal Street, Bandra (East),
Mumbai – 400 001 Mumbai- 400 051
Scrip Code: 500201 Symbol: INDIAGLYCO
Dear Sirs,
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 – Investor Presentation for Q2 & H1FY27
Earnings Conference Call.
Further to our letter bearing no. IGL/SE/2026-27/75 dated 6th November, 2026 and
pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015, an investor
presentation is attached for the information of the investors.
This same is also being hosted on the Company’s website at
www.indiaglycols.com.
This is for your information and record.
Thanking you,
Yours truly,
For India Glycols Limited
Ankur Jain
Head (Legal) & Company Secretary
Encl: A/a
India Glycols Limited
Investor Presentation
Q2 & H1 FY27
BSE : 500201 | NSE : INDIAGLYCO
SAFE HARBOR
This presentation and the following discussion may contain “forward looking statements” by
India Glycols Limited (“IGL” or the company) that are not historical in nature. These forward-
looking statements, which may include statements relating to future results of operations,
financial condition, business prospects, plans and objectives, are based on the current beliefs,
assumptions, expectations, estimates, and projections of the management of IGL about the
business, industry and markets in which IGL operates. These statements are not guarantees of
future performance, and are subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond IGL’s control and difficult to predict, that could cause actual
results, performance or achievements to differ materially from those in the forward-looking
statements. Such statements are not, and should not be construed, as a representation as to
future performance or achievements of IGL. In particular, such statements should not be
regarded as a projection of future performance of IGL. It should be noted that the actual
performance or achievements of IGL may vary significantly from such statements.
CONTENTS
Q2 & H1 FY27 Performance Highlights
Company Overview
Historical Financial Highlights
IGL Group Before the Demerger
Q2 & H1 FY27
Performance Highlights
Q2 & H1 FY27 Performance Snapshot
Strong Broad-Based Growth and an Improving Business Mix towards a Specialty-Led Portfolio, Support the Long-term Value-Creation
Roadmap
• Strong Growth Momentum: Q2 FY27 revenue grew 30% YoY to ₹358 Cr, while H1 revenue increased 26% to ₹713 Cr
• Healthy Earnings Growth: EBITDA grew 26% YoY to ₹52 Cr in Q2 and 25% to ₹113 Cr in H1 FY27; H1 margin remained stable at 15.8%
• Bio-based Specialty Materials Leading Growth: H1 revenue increased 43% YoY to ₹382 Cr, EBITDA up 15% to ₹62 Cr
• Sustainable & Performance Chemicals Demonstrating Operating Leverage: Q2 revenue grew 36% to ₹167 Cr and H1 revenue grew
29% to ₹313 Cr, while EBITDA increased 49% to ₹24 Cr in Q2 and 40% to ₹51 Cr in H1; Margin expanded from 13.0% to 14.2% in Q2 and
from 15.0% to 16.3% in H1
• Improving Business Mix: Bio-Based Specialty Materials increased its share of H1 revenue to 55% from 52%, supporting the shift
toward a more specialty-led portfolio
• Outlook: The speciality materials expected to see steady growth going forward, Performance Chemicals would be the growth driver
followed by introduction novel products and technologies in the mid to longer time frame. The new product pipe line, business
development with diverse partners as well work on newer technology projects.
*EBITDA including JV Share
Note: Q2 FY26 and H1 FY26 figures have been presented on a like-for-like basis and therefore differ from the consolidated results reported to the stock exchanges, which included Spirits & Bio-fuels and
Ennature Biopharma businesses subsequently demerged from India Glycols Limited
The Demerger Creates a Focused Chemicals Company
FROM ONE GROUP TO THREE LISTED COMPANIES
FY26 Consolidated Financials
India Glycols Limited (Pre-demerger)
FY26 Revenue ₹4,211 Cr · FY26 EBITDA ₹690 Cr
IGL Spirits Limited India Glycols Limited Ennature Biopharma Limited
Spirits & Bio-fuels Chemicals Nutraceuticals & plant-based APIs
Revenue ₹2,801 Cr Revenue ₹1,164 Cr Revenue ₹246 Cr
EBITDA ₹492 Cr EBITDA ₹169 Cr EBITDA ₹29 Cr
EBITDA margin 17.6% EBITDA margin 14.5% EBITDA margin 11.9%
71% 25% 4%
of group EBITDA of group EBITDA of group EBITDA
1 share for every 1 IGL share Continues as the Chemicals business 1 share for every 3 IGL shares
WHAT IT MEANS FOR IGL
Visible and valued on its own Own capital allocation Continuity at arm's length
Chemicals was a quarter of group Cash flows go into capacity fill and Ethanol supply and shared Kashipur
EBITDA; it now has its own P&L, specialties, not into spirits or services run on commercial
investor base and valuation pharma capex agreements
IGL at a Glance : A Pioneer in Plant-based Chemicals in India
Since 1989, IGL has converted sugarcane-derived ethanol into ethylene oxide and its derivatives — building blocks for packaging, textiles,
coatings, personal care and pharma
THREE BUSINESS PLATFORMS
4 Decades 300 Acre
Sustainable &
of expertise in Green State-of-the-art Bio-based
Gases
Chemistry Manufacturing facility in Performance
Specialty Materials
Kashipur Chemicals
Bio Glycols, Glycol Ether & GE Bio-amines, green solvents, Industrial, food-grade and
Esters application-led chemistries medical gases
₹1,164 Cr ₹169 Cr
Scaled renewable molecules Specialty-led growth engine; High-purity, reliability-led
with a lower-carbon feedstock includes JV with Clariant supply for essential
FY26 revenue EBITDA
advantage applications
WHAT SETS IGL APART
14.5% 40+
EBITDA margin, +570 bps Countries Global pioneer in bio-EO Integrated, hard-to-replicate chain
01 02
over FY24–26
The world’s 1st producer of Bio-based Ethanol → bio-ethylene → bio-EO →
Ethylene Oxide / Bio-based Glycols / Bio- derivatives at one Kashipur complex, rail-
based Amines and still one of the few linked to ports.
manufacturers to do it at scale
~45% 100+
Structural sustainability tailwind Built-in growth and margin levers
03 04
Export share of sales Customers
Drop-in renewable molecules help Capacity headroom, rising specialty mix
(ex-JV)
customers decarbonize without and R&D-led innovation with global
reformulating. partners.
Following the demerger of its spirits and biopharma businesses, IGL is a pure-play chemicals company
Key Strengths of the Renewable Chemistry Platform
Integrated Bio-EO Deep Process Global, Diversified
Pure-play Focus
Platform Know-how Reach
Dedicated management and
One platform, multiple ways to ~4 decades of expertise, end- 12+ end-markets served across
capital allocation; valued on its
monetise every molecule to-end integration and trusted 40+ countries
own economics
partnerships
Feedstock to Chemistry-led Favourable Experienced
Finished Product Breadth Industry Dynamics Leadership
Flexible sourcing and rail-linked 1 renewable feedstock, 19 Demand shift to bio-based Seasoned board and a
access to global markets derivatisation platforms, 28 chemicals dedicated leadership team for
application functions IGL
One Integrated Platform, Multiple Ways to Monetise Every Molecule
A vertically integrated chain from renewable ethanol to five revenue streams — pioneered by IGL in 1989 and refined over 4 Decades
INTEGRATED VALUE CHAIN INTEGRATED VALUE CHAIN
97% 1989
Bio-Glycols (MEG · DEG · TEG)
Packaging, Polyester Fibre, Coolants
Renewable raw material First to produce EO from
renewable ethanol
Glycol Ethers & GE Esters
Paints, coatings, inks, automotive
Performance Chemicals
Application-led specialty ingredients
Renewable Ethanol
Sugarcane-based,
incl. CarbonSmart Bio-Ethylene Bio-EO
Bio-EO
[Showing first 8,000 characters — download PDF for full document]